[HIGHLIGHTS] The local medical insurance reimbursement rate of domestic new crown drugs reaches 95%, and the maximum self-payment is as low as 30 yuan

According to the latest medical insurance reimbursement policy, domestic new crown drugs can be paid at most as low as 30 yuan. The proportion of self-payment for the domestically produced new crown drug Xiannoxin (prenortevir/ritonavir combination packaging) is 5% for individuals.

Professor Wang Guiqiang, director of the Department of Infectious Diseases of Peking University First Hospital, said: "The highly conservative characteristics of the 3CL target are still effective against the XBB variant"